GE gets FDA nod for Voluson i

AuntMinnie.com staff writers
May 10, 2006

GE Healthcare has received U.S. Food and Drug Administration clearance for its Voluson i 4D compact ultrasound system.

The laptop-sized system is designed specifically for women's healthcare, including obstetric, gynecological, and other applications, according to the Chalfont St. Giles, U.K.-based vendor. Voluson i is now available in the U.S.

By AuntMinnie.com staff writers
May 10, 2006

Related Reading

GE partners with Mayo on 3T MRI, May 9, 2006

GE debuts Lunar Prodigy Primo, May 8, 2006

GE installs first BrightSpeed CT scanner, May 5, 2006

GE installs PET/CT in Boston, April 28, 2006

GE gets FDA nod on Senographe Essential, April 20, 2006

Copyright © 2006 AuntMinnie.com

Latest in Ultrasound
Smfm Ultrasound Ai Fetal Thumbnail
AI assistance improves CHD detection on prenatal ultrasound
January 31, 2025
(A,B) Images from an initial ultrasound examination showed no identifiable lesions and received a consensus ultrasound category of US-1. Nearly the entire liver is visualized, with minimal shadowing (“s”, A and B), and the examination received consensus result of VIS-A. The AFP level was 7.1 ng/mL on assessment six months before the ultrasound, 9.1 ng/mL on assessment three months before examination, and 14.2 ng/mL on assessment on exam day. The AFP result was thus assessed as positive based on a progressive increase on two consecutive tests. The atient was considered to have negative surveillance result according to LI-RADS Ultrasound Surveillance v2017, but positive surveillance result according to LI-RADS Ultrasound Surveillance v2024. (C-D) Axial arterial-phase (C) and portal-venous phase (D) T1-weighted images from subsequent gadoxetic acid-enhanced MRI show a 2-cm arterial-phase hyperenhancing observation (arrow, C) with portal-venous washout (arrow, D) in segment 7. This observation was classified on MRI as LR-5, thus meeting the present study’s reference standard for diagnosis of HCC. The mass is located in the periphery of the liver, an anatomic area where ultrasound visualization can be challenging due to shadowing.
LI-RADS ultrasound surveillance version 2024 improves HCC detection
January 22, 2025
Images depict a 49-year-old female participant with cryptogenic cirrhosis who presented with a 3.2-cm liver lesion. This biopsy-confirmed hepatocellular carcinoma (HCC) with an initial categorization of Liver Imaging Reporting and Data System (LI-RADS) category LR-4 (probably HCC) at CT was upgraded to LR-5 (definitely HCC) at contrast-enhanced ultrasound (CEUS). (A) Precontrast CT images in the liver show vague hypoattenuation in the medial left hepatic lobe (arrows). (B) Arterial phase images demonstrate no definite arterial phase hyperenhancement (arrows). (C) Washout and an enhancing capsule (arrows) on a late-phase image resulted in an LR-4 categorization. (D) B-mode ultrasound shows a round hypoechoic nodule (arrows). (E) An early-phase CEUS image shows clear arterial-phase hyperenhancement (arrows); (F) No washout at one minute (arrows), and (G) late, mild washout at four minutes (arrows) resulted in a CEUS LR-5 categorization.
CEUS resolves indeterminate CT, MRI liver observations
January 21, 2025
Ultrasound Portable
POCUS useful for diagnosis of retained conception tissue
January 15, 2025
Related Stories
187x200 Am Logo
Companies
AuntMinnie.com
Ge Health Care Logo (jan 2023)
Vendors
GE HealthCare
2006 04 17 15 42 48 706
Ultrasound
Contrast-enhanced US picture shows signs of brightening
2005 11 08 15 33 25 706
Ultrasound
Medison America
More in Ultrasound
AI assistance improves CHD detection on prenatal ultrasound
By Amerigo Allegretto
AI boosts detection of major congenital heart defects (CHDs) on prenatal ultrasound, suggest findings presented at the Annual Pregnancy Meeting of the SMFM.
January 31, 2025
Smfm Ultrasound Ai Fetal Thumbnail
LI-RADS ultrasound surveillance version 2024 improves HCC detection
By Amerigo Allegretto
The 2024 version of the LI-RADS Ultrasound Surveillance system improves detection of hepatocellular carcinoma (HCC) over earlier iterations.
January 22, 2025
(A,B) Images from an initial ultrasound examination showed no identifiable lesions and received a consensus ultrasound category of US-1. Nearly the entire liver is visualized, with minimal shadowing (“s”, A and B), and the examination received consensus result of VIS-A. The AFP level was 7.1 ng/mL on assessment six months before the ultrasound, 9.1 ng/mL on assessment three months before examination, and 14.2 ng/mL on assessment on exam day. The AFP result was thus assessed as positive based on a progressive increase on two consecutive tests. The atient was considered to have negative surveillance result according to LI-RADS Ultrasound Surveillance v2017, but positive surveillance result according to LI-RADS Ultrasound Surveillance v2024. (C-D) Axial arterial-phase (C) and portal-venous phase (D) T1-weighted images from subsequent gadoxetic acid-enhanced MRI show a 2-cm arterial-phase hyperenhancing observation (arrow, C) with portal-venous washout (arrow, D) in segment 7. This observation was classified on MRI as LR-5, thus meeting the present study’s reference standard for diagnosis of HCC. The mass is located in the periphery of the liver, an anatomic area where ultrasound visualization can be challenging due to shadowing.
CEUS resolves indeterminate CT, MRI liver observations
By Amerigo Allegretto
Contrast-enhanced ultrasound (CEUS) can resolve some high-risk indeterminate liver observations initially seen on CT or MRI.
January 21, 2025
Images depict a 49-year-old female participant with cryptogenic cirrhosis who presented with a 3.2-cm liver lesion. This biopsy-confirmed hepatocellular carcinoma (HCC) with an initial categorization of Liver Imaging Reporting and Data System (LI-RADS) category LR-4 (probably HCC) at CT was upgraded to LR-5 (definitely HCC) at contrast-enhanced ultrasound (CEUS). (A) Precontrast CT images in the liver show vague hypoattenuation in the medial left hepatic lobe (arrows). (B) Arterial phase images demonstrate no definite arterial phase hyperenhancement (arrows). (C) Washout and an enhancing capsule (arrows) on a late-phase image resulted in an LR-4 categorization. (D) B-mode ultrasound shows a round hypoechoic nodule (arrows). (E) An early-phase CEUS image shows clear arterial-phase hyperenhancement (arrows); (F) No washout at one minute (arrows), and (G) late, mild washout at four minutes (arrows) resulted in a CEUS LR-5 categorization.
POCUS useful for diagnosis of retained conception tissue
By Amerigo Allegretto
Point-of-care ultrasound (POCUS) can be a useful tool for diagnosing the presence of retained conception tissue.
January 15, 2025
Ultrasound Portable
AI guidance leads to better LUS image acquisition by novice users
By Amerigo Allegretto
Healthcare professionals who are not sonography experts can successfully acquire lung ultrasound (LUS) images with AI assistance.
January 15, 2025
Ultrasound Probe2 Social
Ultrasound ablation is effective for treating hyperparathyroidism
By Amerigo Allegretto
Ultrasound-guided thermal ablation techniques are safe and effective in treating patients with secondary hyperparathyroidism.
January 7, 2025
Ultrasound images depict a 63-year-old man who underwent radiofrequency ablation (RFA) for the treatment of secondary hyperparathyroidism. (A–D) 2D images show four hyperplastic parathyroid glands on the right and left sides (marked with crosshairs). The numbers near the crosshairs represent the number of measured trails. (E) Ultrasound-guided infusion of isolation fluid (arrowheads) around the hyperplastic parathyroid gland to protect vital organs such as the trachea (Tr), carotid arteries (CA), and recurrent laryngeal nerve pathway area (arrow). F) Ultrasound-guided RFA of the hyperplastic parathyroid gland. (G) Immediate postoperative contrast-enhanced ultrasound shows no contrast enhancement in the ablation area. The ablation procedures for the other three parathyroid glands were the same as those described above. Image courtesy of the RSNA,
RFA successful for treating malignant thyroid nodules
By Amerigo Allegretto
Radiofrequency ablation (RFA) can successfully treat malignant thyroid nodules with minimal adverse events.
December 13, 2024
Thyroid 400
What can we do to increase global access to imaging?
By Josh Sokol, MD
Outreach and philanthropy will be central themes at RSNA 2024. Ahead of the congress, teleradiologist Josh Sokol, MD, explains why the radiology community must work together to improve access to imaging.
December 1, 2024
The clinical team perform an ultrasound scan at the Nyankunde Hospital, the Democratic Republic of the Congo, where Warren Cooper, MD, has performed operations ranging from repairing broken bones to craniotomies for over a decade.
Inquest into neonatal death highlights ultrasound errors
By Philip Ward
A radiologist and a sonographer failed to diagnose critical conditions in two pregnant women, including a twin baby who died three days after birth, a report has revealed.
November 27, 2024
Digital Justice Scales
CEUS-based radiomics model aids in breast cancer diagnosis
By Amerigo Allegretto
A contrast-enhanced ultrasound (CEUS)-based radiomics model could help accurately diagnose breast cancer.
November 26, 2024
Ultrasound Scanner Computerized 400 (1)
Ultrasound-based deep learning models aid thyroid nodule prediction
By Amerigo Allegretto
A deep learning-based framework incorporating ultrasound images and clinical data can help in thyroid nodule prediction.
November 25, 2024
Thyroid 400
Elastography shows tissue stiffness in athletes with low-back pain
By Amerigo Allegretto
Shear-wave elastography shows tissue stiffness in athletes with low-back pain, which could help guide rehabilitation strategies.
November 22, 2024
Back Pain 400
Page 1 of 513
Next Page